摘要
长效支气管扩张剂是稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)治疗的基石。固定剂量长效β2受体激动剂(long actingβ2 agonist,LABA)/长效抗胆碱能药物(long acting muscarinic antagonist,LAMA)复方制剂被慢性阻塞性肺疾病全球倡议推荐用于COPD的治疗。为了更深入了解已经上市的多种LABA/LAMA复方制剂如维兰特罗/乌美溴铵、茚达特罗/格隆溴铵、福莫特罗/格隆溴铵及奥达特罗/噻拖溴铵等的疗效和安全性,本文对LABA/LAMA一些重要临床研究作一综述,旨在为COPD患者提供个体化的治疗方案。
Long-acting bronchodilation is the cornerstone for the treatment of chronic obstructive pulmonary disease(COPD).Fixed dose combinations of long actingβ2 agonist(LABA)/long acting muscarinic antagonist(LAMA)were recommended for the treatment of symptomatic COPD patients by global guidelines.This review comprehensively described the clinical efficacy and safety of four approved LABA/LAMA fixed-dose combinations:vilanterol/umeclidinium,indacaterol/glycopyrronium,formoterol/aclidinium,and olodaterol/tiotropium,in order to provide a better understanding of the benefits of these therapies and to inform healthcare providers and patients on their appropriate uses.
作者
李倩
毛山
LI Qian;MAO Shan(Department of Respiratory,Nanjing Hospital Affiliated to Nanjing Medical University,Nanjing 210006,Jiangsu Province,China)
出处
《世界临床药物》
CAS
2020年第2期149-154,共6页
World Clinical Drug
基金
南京市科技发展计划项目(201803007)
南京市医学科技发展项目(YKK17119)。
